Senior counsel for the decisions that define value in the life sciences.
Arch and Cross Partners advises boards, leadership teams, and investors in biopharmaceuticals and medtech: corporate strategy, partnering and licensing, M&A, and the executive leadership to carry them through.
The Firm
A partnership built for consequential decisions.
Arch and Cross Partners LLC is a boutique advisory firm serving the life sciences. We work as senior principals only, taking on a limited number of engagements where experience determines outcomes: shaping corporate and portfolio strategy, preparing and executing transactions, and building business development capability where none yet exists.
Our partners have sat on every side of the table, as operators with multibillion-dollar P&L responsibility, as dealmakers on transactions from early-stage licensing to large-scale M&A and divestitures, and as directors and chairmen of public and private companies in the United States and Europe. The partnership itself began at Mallinckrodt, where the two worked side by side on the transactions that reshaped the company. Clients engage us as an extension of their own leadership.
The Record
Across operating, board, and advisory roles, our partners have led:
What We Do
Strategy through execution.
Corporate & Portfolio Strategy
Growth and portfolio strategy, market and indication prioritization, lifecycle planning, and board-level strategic reviews grounded in commercial reality.
M&A & Divestitures
Buy-side and sell-side leadership from screening and valuation through diligence, negotiation, and close, for assets, business units, and whole companies.
Partnering & Licensing
Out-licensing and in-licensing, partner search and evaluation, deal structuring, and negotiation support across global pharma, biotech, and medtech.
Executive & Board Advisory
Fractional C-suite leadership, business development build-outs, investor and partner outreach, and independent counsel to boards and chief executives.
The Partners
Two principals. Decades of operating and deal leadership.
Gary M. Phillips, MD
Partner
A physician-executive with more than 30 years in global biopharmaceuticals across commercial operations, corporate strategy, and business development, Gary has held direct P&L responsibility of up to $1.6 billion and led more than $12 billion in completed M&A and licensing transactions, alongside over $1 billion in divestitures.
He has served as President and CEO of OrphoMed, EVP and Chief Strategy Officer of NYSE-listed Mallinckrodt, commercial leader of multibillion-dollar specialty businesses at Reckitt Benckiser Pharmaceuticals and Bausch + Lomb, and most recently Chief Business Officer of Anaveon. He is Chairman of the Supervisory Boards of Nanobiotix and BioConnection, and a director of Aldeyra Therapeutics, Oryn Therapeutics, and Rheon Medical. A triple graduate of the University of Pennsylvania (BA, Wharton MBA, MD), he is a U.S. Navy veteran, honorably discharged as Lieutenant Commander.
Rick Hoyt
Partner
A strategy and business development executive with more than four decades in pharmaceuticals, Rick has closed transactions with a combined value of more than $10 billion. At Mallinckrodt he led the deal flow that transformed the company from diagnostics, generics, and chemicals into a branded specialty pharmaceutical business, including the $5.6 billion merger with Questcor and the acquisitions of Cadence Pharmaceuticals, Ikaria, and Therakos.
His career at Mallinckrodt and its predecessor companies spanned research chemistry, plant operations, R&D leadership, and corporate strategy, including the company's spin-off from Covidien into an independent public company and, as Chief Strategy Officer, the carve-out of its specialty generics business. Most recently he served as Vice President of Business Development and Licensing at Xeris Biopharma. He holds a BS in Chemistry from the University of Missouri-St. Louis and completed the Executive Development Program at The Wharton School.
Contact
Start the conversation.
Engagements begin with a direct exchange between principals. Write to either partner.
Switzerland · United States